论文部分内容阅读
目的观察依那普利叶酸片辅治H型高血压致急性脑梗死患者的临床效果。方法将120例急性脑梗死患者随机分为观察组与对照组。对照组患者依据2010年缺血性脑卒中诊治指南给予规范治疗,予洛伐他汀、硝苯地平缓释片治疗。观察组在对照组基础上予依那普利叶酸片治疗。对比2组治疗前后血清丙二醛(MDA)、超氧化物歧化酶(SOD)、一氧化氮(NO)、丙皮素(ET),血浆同型半胱氨酸(HCY)水平和美国国立卫生研究院卒中量表(NIHSS)、Barthel评分。结果治疗前2组血清MDA、SOD、NO、ET、NIHSS评分、Barthel评分和血浆HCY水平差异无统计学意义(P>0.05)。治疗后,2组血清MDA、ET、NIHSS评分和HCY水平降低,SOD、NO、Barthel评分升高,且观察组波动幅度大于对照组,差异均有统计学意义(P<0.05)。结论依那普利叶酸片辅治H型高血压致急性脑梗死患者可以明显减轻神经功能缺损程度,改善患者的日常生活能力。分析原因可能与依那普利叶酸片可以有效降低HCY,改善血管舒缩功能有关。
Objective To observe the clinical efficacy of enalaprol folic acid tablets in the treatment of patients with acute cerebral infarction caused by Hypertension. Methods 120 patients with acute cerebral infarction were randomly divided into observation group and control group. Patients in the control group were given standardized treatment according to the guidelines for the diagnosis and treatment of ischemic stroke in 2010, and were treated with lovastatin and nifedipine sustained-release tablets. The observation group was treated with enalapril folate tablets on the basis of the control group. The levels of serum malondialdehyde (MDA), superoxide dismutase (SOD), nitric oxide (NO), endothelin (ET) and plasma homocysteine (HCY) in the two groups were compared before and after treatment with the National Institutes of Health Institute of Stroke Scale (NIHSS), Barthel score. Results There was no significant difference in serum MDA, SOD, NO, ET, NIHSS score, Barthel score and plasma HCY level between the two groups before treatment (P> 0.05). After treatment, the levels of serum MDA, ET, NIHSS and HCY in the two groups decreased, the levels of SOD, NO and Barthel increased, and the fluctuation range of the observation group was larger than that of the control group (P <0.05). Conclusion Enalapril folate tablets can be used to treat patients with acute cerebral infarction induced by Hypertension, which can significantly reduce the degree of neurological deficits and improve their daily living ability. Analysis may be related to enalapril folate tablets can effectively reduce HCY, improve vasomotor function.